Market Trends of Global Expression Vectors Industry
This section covers the major market trends shaping the Expression Vectors Market according to our research experts:
Bacterial expression vectors are Expected to Witness High Growth Over the Forecast Period
Bacterial expression vectors are DNA molecules that are used to transfer foreign genetic material into a host in order to replicate and amplify the foreign DNA sequences as a recombinant molecule. Bacterial expression vectors are found to hold the largest share which can be attributed to the increasing the prevalence of cancer and infectious diseases and focus areas for many companies in the bacterial and plasmid vectors. Recombinant proteins are delivered into target cells using bacteria as a carrier for the treatment of cancer and a number of infectious disorders. The World Health Organization (WHO) reports that cancer is the second biggest cause of death in the world. In 2020, there were 19.3 million new cases of cancer worldwide, and in 2040, there are expected to be 28.4 million new cases. Additionally, the WHO reports that there are numerous dangers to public health around the world, ranging from climate change to a lack of adequate healthcare facilities, with infectious diseases dominating the WHO's list of health hazards for 2019. Such increase in cancer cases boosting the segment growth.
Many companies shifted to increase mergers and acquisitions to acquire more production capabilities. For instance, Thermo Fisher Scientific launched viral vector manufacturing facility in Plainville, Massachusetts, in August 2022, expanding its capabilities in cell and gene therapy. Also in February 2021, Catalent acquired Delphi Genetics and opened a US plasmid manufacturing facility to establish global pDNA development and manufacturing capabilities. Such increasing in development in the segment is further enhancing the growth in the forecast period.
North America is Expected to Dominate the Expression Vectors Market
North America is the largest market for expression vector and is expected to dominate the overall expression vector market due to factors like the presence of well-established healthcare infrastructure in these regions combined with the intense R&D activities carried out. The US expression vector market is driven by factors, such as an increase in the usage of protein technologies, the rapid evolution of the pharmaceutical industry in the region, and investment of government and private companies in synthetic biology research in the region itself.
According to the report of the American Cancer Society, published in January 2021, there is an estimated 1,898,160 new cases of cancer, and 608,570 people died from it. The increasing demand and acceptance of gene and monoclonal antibody-based therapies in the treatment of diseases such as cancer, rare diseases, and other disorders and investment in R&D are driving the growth of the expression vector market in the region.
Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the North America Region
